TITAN er et fortløbende randomiseret, kontrollet, åbent fase III- forsøg, der sammenligner PREZISTA co- administeret med ritonavir (600/ 100 mg x 2) med lopinavir/ ritonavir (400/ 100 mg x 2) hos behandlingserfarne, lopinavir- naive voksne patienter HIV- 1 patienter.
TITAN is an ongoing randomised, controlled, open-label Phase III trial comparing PREZISTA co-administered with ritonavir (600/100 mg b.i.d.) versus lopinavir/ritonavir (400/100 mg b.i.d) in treatment-experienced, lopinavir naïve HIV-1 infected adult patients.